Revvity (NYSE:RVTY) 株価情報

Revvity

Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.

Revvity Inc

HC Wainwright &amp; Co. analyst Robert Burns reiterates SpringWorks Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWTX#NASDAQ">SWTX</a>) with a Buy and maintains $74 price target.

News

Price Target

Reiteration

Analyst Ratings

SWTX

HC Wainwright & Co. Reiterates Buy on SpringWorks Therapeutics, Maintains $74 Price Target

MCHP

Microchip Technology Launched MPLAB XC Unified Compiler Licenses For Its MPLAB XC8, XC16, XC-DSC and XC32 C Compilers

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.laserphotonics.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Laser+Photonics+Corporation&amp;index=1&amp;md5=223dc3d3ec3a60d49aba12f490f75c5b">Laser Photonics Corporation</a> (LPC) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LASE#NASDAQ">LASE</a>), a leading global developer of industrial laser systems for cleaning and other material processing applications, in partnership with its sibling company Fonon Technologies, announced today the receipt of a second order for its <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.fonon.us%2Fproducts%2Fdefensetech-mrls-portable-finishing-laser-1020&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=DefenseTech+MRLS+Portable+Finishing+Laser&amp;index=3&amp;md5=223a07b9d89ac41eff38d88550ae268c">DefenseTech MRLS Portable Finishing Laser</a> (MF-1020) handheld cleaning system. This order was facilitated once again through their distribution partner, <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fincrediblesupply.com%2F&amp;esheet=54212399&amp;newsitemid=20250224082074&amp;lan=en-US&amp;anchor=Incredible+Supply+%26amp%3B+Logistics&amp;index=4&amp;md5=d2db227391448095ee4cf287ffd15f20">Incredible Supply &amp; Logistics</a> (ISL), an award-winning product distribution and third-party logistics (3PL) company.
The DTMF-1020 air-cooled handheld pulsed laser cleaning system, equipped with dual-axis technology, streamlines maintenance processes. This system will be utilized by the same Navy command in Virginia Beach that ordered the first unit.

Government

Regulations

LASE

Laser Photonics Secures Second Order for DefenseTech MRLS Laser Cleaning System

Earnings

ATCH

Reported Earlier, AtlasClear Holdings Q2 EPS $(1.11) Down From $2.22 YoY, Sales $2.75M

SOAR

Volato Announced Today That It Has Begun Bitcoin Mining Operations, Marking An Early But Significant Step In Its Broader Exploration Of Aviation-integrated Cryptocurrency Mining

Leerink Partners analyst Mike Kratky initiates coverage on Beta Bionics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBNX#NASDAQ">BBNX</a>) with a Outperform rating and announces Price Target of $28.

Initiation

BBNX

Leerink Partners Initiates Coverage On Beta Bionics with Outperform Rating, Announces Price Target of $28

<ul>
<li>SYMBRAVO demonstrated statistically significantly greater migraine treatment response compared to prior treatment with an oral CGRP inhibitor (p&lt;0.001, mTOQ-4 total score, primary endpoint)</li>
<li>2-hour pain freedom for most attacks reported at least half the time by 47.9% of patients after SYMBRAVO versus 1.0% after oral CGRPs (p&lt;0.001)</li>
<li>24-hour or greater sustained pain relief after a single dose reported by 47.9% of patients after SYMBRAVO versus 16.7% after oral CGRPs (p&lt;0.001)</li>
<li>Ability to quickly return to normal activities reported by 51.0% of patients after SYMBRAVO versus 11.5% after oral CGRPs (p&lt;0.001)</li>
<li>SYMBRAVO improved quality of life compared to after oral CGRPs (p&lt;0.001, MSQ)</li>
</ul>

AXSM

Axsome Therapeutics Unveils SYMBRAVO Success In EMERGE Phase 3 Trial, Paving The Way For Enhanced Migraine Treatment For CGRP Inhibitor Non-Responders

PepGen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced initial positive clinical data from the 5 and 10 mg/kg dose cohorts in the ongoing FREEDOM-DM1 Phase 1 trial investigating PGN-EDODM1 in myotonic dystrophy type 1 (DM1).
"These results far exceeded our expectations for splicing correction following a single dose of PGN-EDODM1. Mis-splicing is the underlying cause of DM1 pathology, and we believe the mean splicing correction observed at 28 days following a single dose of PGN-EDODM1 at 10 mg/kg in the FREEDOM clinical trial surpasses those reported to date in multi-dose clinical trials of up to nine months in duration in patients with DM1. We believe this is a strong indicator of our EDO technology's potential to deliver therapeutic oligonucleotides to the nucleus and PGN-EDODM1's potential to address the underlying cause of disease," said James McArthur, PhD, President and CEO of PepGen. "We believe these results provide initial validation of PGN-EDODM1's ability to selectively bind the pathogenic CUG-repeat DMPK RNA and we look forward to evaluating PGN-EDODM1 with more doses over longer time periods in our FREEDOM2-DM1 multiple ascending dose study. Based on these initial results, we aim to build on the significant correction of mis-splicing observed in this single-dose study to potentially provide improved functional benefit for patients who currently have no available approved therapeutic options."

PEPG

PepGen Reports Early Data From FREEDOM-DM1 Trial for Myotonic Dystrophy

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Balchem (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCPC#NASDAQ">BCPC</a>) with a Buy and maintains $190 price target.

BCPC

HC Wainwright & Co. Reiterates Buy on Balchem, Maintains $190 Price Target

B of A Securities analyst Peter Henderson maintains Live Nation Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>) with a Buy and raises the price target from $149 to $175.

B of A Securities Maintains Buy on Live Nation Entertainment, Raises Price Target to $175

Mr. Doogue's ascension to CEO comes after 27 years of rising through the leadership ranks at Allegro, during which time he enabled many of Allegro's disruptive technologies, originally as an engineer and later as a business leader. Immediately prior to this promotion, Mr. Doogue served as Allegro's Executive Vice President and its first Chief Technology Officer (CTO), leading technology development and worldwide operations, which includes manufacturing, procurement, and quality. Mr. Doogue also previously served as the Company's Senior Vice President of Technology and Products, which included direct oversight of each of the Company's business units. As a testament to his roots as an engineer and technology innovator, Mr. Doogue personally holds 75 semiconductor-related U.S. patents.

ALGM

Allegro MicroSystems Names Mike Doogue As Chief Executive Officer

B of A Securities analyst John Murphy downgrades Rivian Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) from Neutral to Underperform and lowers the price target from $13 to $10.

Downgrades

RIVN

B of A Securities Downgrades Rivian Automotive to Underperform, Lowers Price Target to $10

IVVD

Invivyd Says FDA Declined Its Request To Expand Existing Emergency Use Authorization Of PEMGARDA To Include Treatment Of Mild-to-moderate COVID-19 For Immunocompromised Persons Who Have No Alternative Therapeutic Options

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Neurocrine Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBIX#NASDAQ">NBIX</a>) with a Buy and maintains $185 price target.

NBIX

HC Wainwright & Co. Reiterates Buy on Neurocrine Biosciences, Maintains $185 Price Target

Nektar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKTR#NASDAQ">NKTR</a>) and TrialNet, an international clinical trial network at the forefront of diabetes research, today announced a new collaboration agreement to evaluate Nektar's rezpegaldesleukin in patients with new onset stage 3 type 1 diabetes mellitus (T1D).
&nbsp;
Rezpegaldesleukin is a novel agonistic T regulatory (Treg) cell biologic that is designed to both dampen the inflammatory response and simultaneously restore immune balance by directly expanding functional Treg cells and engaging multiple immunoregulatory pathways. Tregs are known to play a key role in the pathogenesis of T1D.1
Under the agreement, TrialNet will conduct the Phase 2 randomized, double-blind, placebo-controlled, clinical trial to investigate the safety and potential efficacy of rezpegaldesleukin in approximately 70 adults and children with new onset stage 3 T1D. Nektar will supply rezpegaldesleukin for the trial and will provide support for the study, including pharmacokinetic and other analyses. Nektar will retain all rights to the rezpegaldesleukin program under the collaboration.

NKTR

Nektar Therapeutics and TrialNet Partner to Study Rezpegaldesleukin for Type 1 Diabetes

Biotech

Guidance

Health Care

General

BCRX

Biocryst Pharmaceuticals Expects To Approach Quarterly Positive EPS And Positive Cash Flow In The Second Half Of 2025, And To Be Profitable On An EPS Basis, With Positive Cash Flow, For Full Year 2026

Microsoft Corp.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) has reportedly begun to cancel leases for a significant portion of its AI data center capacity in the United States, as per a recent report by TD Cowen.
What Happened: TD Cowen disclosed on Friday that Microsoft has nullified leases equivalent to &#8220;a couple of hundred megawatts&#8221; of capacity, <a href="https://www.bloomberg.com/news/articles/2025-02-24/microsoft-cancels-leases-for-ai-data-centers-analyst-says">Bloomberg</a> reported on Monday. Additionally, the tech giant has also ceased the conversion of so-called statements of qualifications, which usually lead to formal leases. This strategy is reminiscent of tactics previously employed by competitors like Meta Platforms Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) when they decided to reduce capital expenditure.
TD Cowen&#8217;s report also hints at Microsoft&#8217;s gradual retreat from data center construction and acquisition.&nbsp;The report indicates that Microsoft has let agreements totaling over a gigawatt at larger sites expire and has withdrawn from several deals, each involving approximately 100 megawatts.
SEE ALSO: <a href="https://www.benzinga.com/news/25/02/43901332/biggest-cage-match-ever-mark-cuban-warns-of-a-coming-clash-says-musks-ai-implementation-will-directly-challenge-trumps-grip-on-control">&#8216;Biggest Cage Match Ever&#8217;—Mark Cuban Warns Of A Coming Clash, Says Musk&#8217;s AI Implementation Will Directly Challenge Trump&#8217;s Grip On Control</a>
Why It Matters: This development comes unexpectedly as in January, Microsoft announced its plans to invest around $80 billion in developing AI-powered data centers and deploying AI and cloud-based applications globally. Microsoft&#8217;s possible reduction in spending and data center construction sparks concerns about whether the company is becoming more cautious about future demand.
According to TD Cowen&#8217;s analysts, these changes may suggest that Microsoft is potentially facing an oversupply situation. They also speculated that Microsoft&#8217;s partnership with OpenAI could be shifting in ways that&nbsp;mean the software giant won&#8217;t need the same level of investments. The analysts, however, stated that they are awaiting more details on this.
In January,&nbsp;<a href="https://www.benzinga.com/25/01/42806852/microsoft-pauses-construction-on-33-billion-mount-pleasant-data-center-project-cites-technology-changes-and-design-re-evaluation">Microsoft paused construction</a>&nbsp;on parts of its ambitious data center project in Mount Pleasant, citing changes in technology and design re-evaluation. This move, coupled with the recent lease cancellations, could signal a shift in Microsoft&#8217;s data center strategy.
<ul>
<li>READ MORE: <a href="https://www.benzinga.com/markets/equities/25/02/43905646/nvidia-set-for-clear-beat-and-raise-special-as-ai-demand-surges-says-dan-ives">Nvidia Set For &#8216;Clear Beat And Raise Special&#8217; As AI Demand Surges, Says Dan Ives</a></li>
</ul>
Image via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.<a href="https://www.benzinga.com/apis?utm_source=benzinga.com&amp;utm_campaign=article-bottom" rel="noreferrer noopener" target="_blank"></a>

Markets

Tech

MSFT

Microsoft Pulls Plug On AI Data Center Leases, Says Analyst: Oversupply Situation Likely

AN2 Selects QOL-B as New Phase 3 Primary Efficacy Endpoint
Goal to Accelerate Unblinding Phase 3 Data in Q2 2025 Ahead of Potential FDA Meeting

ANTX

AN2 Therapeutics Advances Phase 3 EBO-301 Trial Wih PRO-Based QOL-B Endpoint, Setting Stage For Potential Registrational Pathways

EV giant Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) will refresh its more premium car offerings- the Model S and Model X- later this year, senior company executive Lars Moravy said in an interview published on Sunday.
What Happened:&nbsp;Moravy, in an interview with&nbsp;Ryan McCaffrey&nbsp;recorded on Feb.13 and published on Sunday,&nbsp;said that the company intends to show its Model S and X vehicles &#8220;some love&#8221; and refresh them later this year.
Tesla last refreshed the Model S and X in 2021. 
In the past two years, the company has focussed on refreshing its cheaper, mass-market offerings. 
Tesla launched a&nbsp;<a href="https://www.benzinga.com/news/24/02/36921718/youtuber-marques-brownlee-reviews-refreshed-model-3-calls-it-teslas-most-important-car-i-am-impresse" target="_blank" rel="noreferrer noopener">refreshed Model 3 in Aug. 2023&nbsp;</a>in China and in the U.S. months later in January 2024. In January this year, the company also launched a <a href="https://www.benzinga.com/25/02/43772576/tesla-to-start-delivering-shanghai-made-refreshed-model-ys-next-week">refreshed version of its best-selling Model Y SUV. </a>
Moravy said that the company focussed on refreshing the Model 3 and Y first as they are higher volume vehicles and refreshing them was needed for the company to stay competitive. However, the S and X are not going anywhere anytime soon, Moravy said.
&#8220;As Elon says, we definitely there&#8217;s some nostalgia to them and like keeping them around and like we don&#8217;t have any immediate plans to change that,&#8221; he said.
Why It Matters: The refreshes come amid concerns about an aging car lineup. Tesla&#8217;s latest offering is its Cybertruck which it started delivering in Nov. 2023. The vehicle, however, is a truck and caters to a different customer demographic. 
The latest car from Tesla is the Model Y SUV, whose production the company started in January 2020. 
The Model X, however, is Tesla&#8217;s <a href="https://www.benzinga.com/tech/24/12/42496103/teslas-model-s-model-x-and-cybertruck-now-have-the-same-starting-price-which-to-buy">priciest offering in the U.S</a>. The base version of the Model X starts at $84,990, pricier than even the Cybertruck or Model S whose base versions start at $79,990.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/02/43905539/elon-musk-led-spacex-to-undertake-starships-8th-test-flight-on-friday" target="_blank" rel="noreferrer noopener">Elon Musk&#8217;s SpaceX To Undertake Starship&#8217;s 8th Test Flight On Friday</a></li>
<li></li>
</ul>
Image via Tesla

TSLA

Tesla To Launch Refreshed Model S, X Later This Year, Says Senior Exec

Eyenovia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) ("Eyenovia" or the "Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet&#xAE; device, today announced that it has entered into an amendment to its outstanding senior secured convertible debt due November 1, 2025 (the "Amendment").The Amendment defers the Company's monthly interest and amortization payments from March 2025 through September 2025. Additionally, the Amendment allows the full conversion of the debt into common shares of the Company commencing on April 1, 2025, at a price of $1.68 per share.

EYEN

Eyenovia Allows Full Debt Conversion to Common Shares at $1.68 Starting April 2025, Defers Payments Until September 2025

Press Releases

Scale Biosciences and Revvity's BioLegend Launch First-of-its-Kind Solution for High Parameter Protein Profiling of Single Cells

Revvity Broadens Relationship with Genomics England to Advance Genomics in the UK

Revvity to Present at J.P. Morgan Healthcare Conference

Revvity Announces FDA Clearance for First Automated Free Testosterone Test

Revvity to Hold Earnings Call on Friday, January 31, 2025; Provides Update on Financial Performance

Revvity and Element Biosciences Collaborate to Advance Sequencing-based IVD Neonatal Testing

Revvity Board Declares Quarterly Dividend

Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2024

Revvity to Present at Upcoming Investor Conferences

Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group

RVTY

Agilent Technologies

AbCellera Biologics

Adaptive Biotechnologies Corporation - Common Stock

Adaptive Biotechnologies

Avantor

Azenta

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories

BioLife Solns

Bruker

Charles River Laboratories International, Inc. Common Stock

Charles River

Danaher

Evotec SE - American Depositary Shares each representing 1/2 of one ordinary share

Comments

Revvity

ニュース

パートナーシップ

ベンジンガ・グローバル